Pembrolizumab May Substantially Up Cervical Cancer Survival Available to Purchase

In the KEYNOTE-826 trial, the addition of the PD-1 inhibitor pembrolizumab to standard-of-care chemotherapy significantly prolonged progression-free survival and overall survival in patients with metastatic, recurrent, or persistent cervical cancer. These findings could define the new standard of care in these cases.